Graham Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Graham Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92.8K	Sell	43,556 -8,036	-16%	-$13.8K	﹤0.01%	1159
2026 Q1	$87.2K	Sell	51,592 -24,773	-32%	-$109K	﹤0.01%	1056
2025 Q4	$396K	Buy	76,365 +30,443	+66%	+$156K	0.01%	727
2025 Q3	$240K	Buy	+45,922	New	+$239K	﹤0.01%	970
2023 Q4	–	Sell	-10,123	Closed	-$67.6K	–	973
2023 Q3	$67.6K	Buy	+10,123	New	+$75.1K	﹤0.01%	953
2022 Q4	–	Sell	-41,590	Closed	-$222K	–	1028
2022 Q3	$222K	Sell	41,590 -795	-2%	-$4.77K	0.01%	971
2022 Q2	$169K	Buy	+42,385	New	+$146K	0.01%	935
2022 Q1	–	Sell	-10,047	Closed	-$40K	–	882
2021 Q4	$40K	Buy	+10,047	New	+$76.6K	﹤0.01%	525

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Graham Capital Management's ALDX Position: Q2 2026 in Review

Graham Capital Management reduced its Aldeyra Therapeutics (ALDX) stake by 16% in Q2 2026, selling an estimated $13.8K and leaving 43,556 shares worth $92.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1159.

Graham Capital Management first reported a position in ALDX in Q4 2021 and has held it in 8 quarters since. The position peaked at $396K in Q4 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Graham Capital Management held 43,556 shares of Aldeyra Therapeutics worth $92.8K as of Q2 2026.
Graham Capital Management sold 8,036 Aldeyra Therapeutics shares in Q2 2026, an estimated $13.8K.
Aldeyra Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1159 holding.
Graham Capital Management first reported a position in Aldeyra Therapeutics in Q4 2021 and has held it in 8 quarters since.
Graham Capital Management's Aldeyra Therapeutics position peaked at $396K in Q4 2025.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.